Pre-Clinical CROs Market outlook to 2027 | Charles River, Eurofins Scientific, WuXi AppTec, Medpace, ICON

The global pre-clinical CROs market is expected to reach US$ 8,412.9 Mn in 2027 from US$ 4,282.4 Mn in 2018. The market is estimated to grow with a CAGR of 8.1% from 2019-2027.

The global pre-clinical CROs market, based on service, has been segmented into bio-analysis and DMPK studies, toxicology and other services. The toxicology segment held a largest share of the market in 2018. Moreover, the same segment is anticipated to register the highest CAGR in the market during the forecast period as toxicology testing plays a vital role in drug discovery process to evaluate the safety of the drug candidate. Moreover, the test is also one of the most reliable and commonly performed that is taken into consideration for translation of animal responses into an understanding risk among human subjects.

Get sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00003316/?opr-10144

The major players operating in the pre-clinical CROs market include, Covance, Inc., Charles River, Eurofins Scientific, PRA Health Sciences, WuXi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC, Parexel International Corporation, ICON Plc, and MD Biosciences among the others. The market has witnessed various organic as well as inorganic developments during recent years in the pre-clinical CROs market. For instance, in September 2019, Pharmaceutical Product Development, LLC (PPD) expanded its bio-analytical laboratory in Richmond, Virginia, enhancing immunochemistry, biomarker and chromatography services for biopharmaceutical clients.

Increasing R&D expenditures and high cost of drug development process in the developed countries have been boosting the market over the years. However, stringent regulations for conduction of clinical trials and variations in the GMP guidelines across countries around the globe are likely to have a negative impact on the growth of the market in the coming years.

The global pre-clinical CROs market by service was segmented as, bio-analysis & DMPK studies, toxicology, and other services. In 2018, toxicology segment held the largest share of the market. The in-vitro and in-vivo toxicology services helps to bolster the ability of determination of potential risk factors in the early process of drug development. The toxicology studies are required to establish the toxicological profiles of new drug molecules prior to their administration in humans.

The major factors driving the growth of outsourcing activities by companies are, cutting costs, need for innovations, increased speed and agility, and accessing specialized knowledge and technologies. A decreasing percentage of profits has become a primary concern for pharmaceutical companies over the past decade. As per an analysis by PhRMA, around $0.8 to $1.7 billion is estimated to be invested by the pharmaceutical industry in R&D to bring a new drug to market. Hence, with an increase in the R&D expenditure, the need for pre-clinical services is expected.

The report segments the global pre-clinical CROs market as follows:

Global Pre-Clinical CROs Market – By Service

Bio-Analysis and DMPK Studies
Toxicology
Other Services
Global Pre-Clinical CROs Market – By End User

Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

Buy Now @ https://www.theinsightpartners.com/buy/TIPRE00003316/?opr-10144

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

This release was published on openPR.